These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 29313565)

  • 1. Utilisation of lipid-lowering therapies in outpatient settings in Poland: epidemiological survey Economedica Dyslipidaemia 2015.
    Szymański FM; Płatek AE; Ryś A; Semczuk-Kaczmarek K; Krzowski B; Wróbel K; Filipiak KJ
    Kardiol Pol; 2018; 76(3):648-654. PubMed ID: 29313565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe.
    Halcox JP; Tubach F; Lopez-Garcia E; De Backer G; Borghi C; Dallongeville J; Guallar E; Medina J; Perk J; Sazova O; Sweet S; Roy C; Banegas JR; Rodriguez-Artalejo F
    PLoS One; 2015; 10(2):e0115270. PubMed ID: 25692692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).
    Zhao S; Wang Y; Mu Y; Yu B; Ye P; Yan X; Li Z; Wei Y; Ambegaonakr BM; Hu D;
    Atherosclerosis; 2014 Aug; 235(2):463-9. PubMed ID: 24950001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.
    Shehab A; Al-Rasadi K; Arafah M; Al-Hinai AT; Al Mahmeed W; Bhagavathula AS; Al Tamimi O; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FOAS; Alawadhi M; Amin H; Al-Hashmi K; Oulhaj A
    Curr Vasc Pharmacol; 2018; 16(4):368-375. PubMed ID: 28677510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.
    Aguiar C; Alegria E; Bonadonna RC; Catapano AL; Cosentino F; Elisaf M; Farnier M; Ferrières J; Filardi PP; Hancu N; Kayikcioglu M; Mello E Silva A; Millan J; Reiner Ž; Tokgozoglu L; Valensi P; Viigimaa M; Vrablik M; Zambon A; Zamorano JL; Ferrari R
    Atheroscler Suppl; 2015 Sep; 19():1-12. PubMed ID: 26315511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS).
    Devroey D; Radermecker RP; Van der Schueren BJ; Torbeyns B; Jaken RJ
    Int J Clin Pract; 2014 Feb; 68(2):180-7. PubMed ID: 24308644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
    Kei A; Liberopoulos E; Tellis K; Rizzo M; Elisaf M; Tselepis A
    Eur J Clin Invest; 2013 Jul; 43(7):698-707. PubMed ID: 23600368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of the intensity of lipid-lowering medications on the LDL cholesterol treatment goals of Asian patients with dyslipidaemia in primary care.
    Tan NC; Goh CC; Goh SC; Koh YL; Koh KH
    J Clin Pharm Ther; 2016 Dec; 41(6):677-683. PubMed ID: 27641514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
    Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
    Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
    Keating GM; Croom KF
    Drugs; 2007; 67(1):121-53. PubMed ID: 17209672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia.
    Katabami T; Murakami M; Kobayashi S; Matsui T; Ujihara M; Takagi S; Higa M; Ichijo T; Ohta A; Tanaka Y
    J Int Med Res; 2014 Apr; 42(2):457-67. PubMed ID: 24595147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting.
    Simpson RJ; Tunceli K; Ramey DR; Neff DR; Kern DM; Hsieh HM; Wertz DA; Stephenson JJ; Marrett E; Tomassini JE; Jacobson TA
    J Clin Lipidol; 2013; 7(5):399-407. PubMed ID: 24079280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.
    Reiner Ž; De Backer G; Fras Z; Kotseva K; Tokgözoglu L; Wood D; De Bacquer D;
    Atherosclerosis; 2016 Mar; 246():243-50. PubMed ID: 26812002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dyslipidaemia pattern and prevalence among type 2 diabetes mellitus patients on lipid-lowering therapy at a tertiary hospital in central South Africa.
    Pitso L; Mofokeng TRP; Nel R
    BMC Endocr Disord; 2021 Aug; 21(1):159. PubMed ID: 34365977
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.